0.22 1.03
NASDAQ : Health Technology
Prev Close 21.30
Open 21.26
Day Low/High 21.23 / 21.82
52 Wk Low/High 6.23 / 37.25
Volume 14.89K
Avg Volume 116.50K
Exchange NASDAQ
Shares Outstanding 8.33M
Market Cap 181.49M
EPS 0.80
P/E Ratio 8.19
Div & Yield N.A. (N.A)

Latest News

Relative Strength Alert For XOMA

Relative Strength Alert For XOMA

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

XOMA Announces Multiple New License Agreements For Proprietary Phage Display Libraries

XOMA Announces Multiple New License Agreements For Proprietary Phage Display Libraries

Expands portfolio of partner-funded programs with potential for milestone and royalty payments

XOMA Announces Positive Results From Its Phase 2 Proof-Of-Concept Study Of Prolactin Inhibition

X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants

XOMA Presents Positive Data From PTH1R Monoclonal Antibody Program

Unmet medical needs in parathyroid hormone-related hypercalcemia contribute to potential partnering value of overall portfolio

XOMA Announces Four Presentations At The 2017 ENDO Meeting

Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia

XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation

Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy

XOMA Appoints Matthew Perry To Its Board Of Directors

Company outlines new strategic imperatives and value drivers

TheStreet Quant Rating: C- (Hold)